Table 3.
Total patient-days after discharge and median duration of treatment with each anticoagulant drug during the study period (n = 958 patients)
| Anticoagulant | Total patient-days per anticoagulant in FOCUS during the first follow-up yeara | Median duration of treatment (IQR) |
|---|---|---|
| Low molecular weight heparin | 14 437 | 48 (42–181) |
| Fondaparinux | 135 | 135 (135–135) |
| Rivaroxaban | 141 772 | 365 (213–365) |
| Apixaban | 69 917 | 365 (220–365) |
| Edoxaban | 9866 | 324 (220–365) |
| Dabigatran | 10 597 | 316 (164–365) |
| VKA—Phenprocoumon | 33 566 | 322 (187–365) |
| VKA—Warfarin | 707 | 149 (136–154) |
| Other | 229 | 229 (229–229) |
| Any anticoagulant | 281 541 | 329 (142–365) |
IQR, interquartile range; VKA, vitamin K antagonist.
a
The FOllow-up after aCUte pulmonary emboliSm (FOCUS) study prospectively collected data on the type and duration of anticoagulant treatment in each patient, including switches from one anticoagulant to another, the exact date of discontinuation, and any resumption of anticoagulant treatment after discontinuation.